SequelSEC

Turn Therapeutics Inc. TTRX

Pharmaceutical Preparations · CIK 0002023016 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2026-06-30
Operating income
-$1.63M
Fiscal year ended 2026-06-30
Free cash flow
Unavailable
Fiscal year ended 2026-06-30

Turn Therapeutics Inc. (TTRX) reported net income of -$5.85M for the fiscal year ended 2026-06-30. This page shows 8 annual periods of income statement, balance sheet and cash flow figures normalized from Turn Therapeutics Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Turn Therapeutics Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-30
RevenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$1.63M-$1.25M-$2.19M-$1.91M-$1.37M-$385.00K-$328.96K-$672.99K
Net income-$5.85M-$970.97K$279.07K-$1.90M-$1.24M-$328.55K-$323.13K-$666.44K
Research & development$475.06K$109.43K$34.93K$158.70K$62.68K$9.26K$9.77K$153.28K
Weighted-average diluted sharesshares 29.79Mshares 29.48MUnavailableshares 27.98Mshares 27.49Mshares 26.96MUnavailableshares 26.65M
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expenseUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Diluted EPS$-0.20$-0.03Unavailable$-0.07$-0.05$-0.01Unavailable$-0.03
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$1.15M$1.14M$2.16M$1.75M$1.30M$375.74K$319.19K$519.71K
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Turn Therapeutics Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-30
Cash & equivalents$9.95M$11.01M$4.03M$513.70KUnavailableUnavailable$498.29K$498.29K
Total assets$16.96M$18.64M$12.16M$4.30MUnavailableUnavailable$2.05MUnavailable
Current assets$10.43M$11.45M$5.20M$3.29MUnavailableUnavailable$1.10MUnavailable
Total liabilities$16.27M$12.53M$7.48M$3.79MUnavailableUnavailable$2.23MUnavailable
Current liabilities$8.76M$5.13M$6.00M$2.31MUnavailableUnavailable$707.93KUnavailable
Total equity incl. NCI$686.89K$6.12M$4.69M$504.02K$1.77M$818.71K-$177.43K-$414.30K
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt$6.06M$5.94MUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Cash flow

Turn Therapeutics Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-30
Operating cash flow-$923.36K-$1.63M-$1.18M-$588.61K-$499.97K-$298.06K-$430.54KUnavailable
Capital expendituresUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Investing cash flow-$5.80K-$12.23K-$31.44K-$89.79KUnavailableUnavailable-$7.84KUnavailable
Financing cash flow$1$7.79M$3.18M$594.62K$2.15M$998.09K$522.21KUnavailable
Net change in cashUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Stock-based compensation$419.23K$280.83K$256.38K$39.08K$47.18K$76.60K$37.81KUnavailable
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

Turn Therapeutics Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-30
Free cash flowUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio1.19x2.23x0.87x1.43xUnavailableUnavailable1.55xUnavailable
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equity8.83x0.97xUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open TTRX in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-12View SEC filing
10-Q · Filed 2026-05-11View SEC filing
10-K · Filed 2026-03-31View SEC filing
10-Q · Filed 2025-11-13View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.